Utilization of Select Products for Migraine Treatment and Prevention: A Descriptive Analysis

In this report, we examined utilization patterns of several products indicated for the preventive treatment or acute treatment of migraine (eptinezumab, erenumab-aooe, fremanezumab, galcanezumab, rimegepant, and ubrogepant). The study period includes data from May 1, 2018 to September 30, 2021. We executed this request on Merative™ MarketScan® Research Databases on August 24, 2022.